{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T20:24:01Z","timestamp":1776025441988,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.mehy.2021.110704","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:05:09Z","timestamp":1634169909000},"page":"110704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The cell of cancer origin provides the most reliable roadmap to its diagnosis, prognosis (biology) and therapy"],"prefix":"10.1016","volume":"157","author":[{"given":"Rachita","family":"Pandya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Grace San Diego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talha","family":"Shabbir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnav P.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Dhahbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanford H.","family":"Barsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, cellular senescence, and cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0010","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.mehy.2021.110704_b0015","first-page":"297","article-title":"Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening","volume":"68","author":"Smith","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.mehy.2021.110704_b0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 Years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.mehy.2021.110704_b0025","doi-asserted-by":"crossref","first-page":"110171","DOI":"10.1016\/j.mehy.2020.110171","article-title":"Why is cancer so common a disease in people yet so rare at a cellular level?","volume":"144","author":"Ferrell","year":"2020","journal-title":"Med Hypotheses"},{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.suronc.2010.02.002","article-title":"Combination cancer immunotherapy \u201cexpanding Paul Ehrlich\u2019s magic bullet concept\u201d","volume":"21","author":"Elliott","year":"2012","journal-title":"Surg Oncol"},{"issue":"15","key":"10.1016\/j.mehy.2021.110704_b0035","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1073\/pnas.89.15.7036","article-title":"Similarity of spontaneous germinal and in vitro somatic cell mutation rates in humans: Implications for carcinogenesis and for the role of exogenous factors in \u201cspontaneous\u201d germinal mutagenesis","volume":"89","author":"Kuick","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mehy.2021.110704_b0040","first-page":"1","article-title":"Cancer morphology, carcinogenesis and genetic instability: a background","author":"Bignold","year":"2006","journal-title":"EXS"},{"issue":"20","key":"10.1016\/j.mehy.2021.110704_b0045","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMra0802968","article-title":"Inherited susceptibility to common cancers","volume":"359","author":"Foulkes","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mehy.2021.110704_b0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","article-title":"Hereditary Cancer Predisposition Syndromes","volume":"23","author":"Garber","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7381","key":"10.1016\/j.mehy.2021.110704_b0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrc.2017.102","article-title":"An evolutionary perspective on field cancerization","volume":"18","author":"Curtius","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.mehy.2021.110704_b0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-009-0504-0","article-title":"Mammary field cancerization: Molecular evidence and clinical importance","volume":"118","author":"Heaphy","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0070","article-title":"Retinoblastoma","volume":"1","author":"Dimaras","year":"2015","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"10.1016\/j.mehy.2021.110704_b0075","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cjp2.155","article-title":"Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers","volume":"6","author":"McCrorie","year":"2020","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.mehy.2021.110704_b0080","series-title":"BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer","author":"Petrucelli","year":"1993"},{"issue":"2","key":"10.1016\/j.mehy.2021.110704_b0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.mehy.2021.110704_b0090","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes and Cancer"},{"key":"10.1016\/j.mehy.2021.110704_b0095","doi-asserted-by":"crossref","unstructured":"Guha T, Malkin D. Inherited TP53 mutations and the Li-fraumeni syndrome. Cold Spring Harb Perspect Med 2017;7. https:\/\/doi.org\/10.1101\/cshperspect.a026187.","DOI":"10.1101\/cshperspect.a026187"},{"key":"10.1016\/j.mehy.2021.110704_b0100","unstructured":"Jasperson KW, Patel SG, Ahnen DJ. APC-Associated Polyposis Conditions. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020."},{"key":"10.1016\/j.mehy.2021.110704_b0105","article-title":"RB1, Development, and Cancer. NIH Public","volume":"94","author":"Chinnam","year":"2011","journal-title":"Access"},{"issue":"13","key":"10.1016\/j.mehy.2021.110704_b0110","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJM199609263351307","article-title":"Seminars in medicine of the Beth Israel Hospital, Boston: The RET proto- oncogene in multiple endocrine neoplasia type 2 and Hirschsprung\u2019s disease","volume":"335","author":"Flier","year":"1996","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.mehy.2021.110704_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4252\/wjsc.v4.i3.17","article-title":"Thoughts about cancer stem cells in solid tumors","volume":"4","author":"La Porta","year":"2012","journal-title":"World J Stem Cells"},{"issue":"9","key":"10.1016\/j.mehy.2021.110704_b0120","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ejca.2006.01.031","article-title":"Breast cancer stem cells: An overview","volume":"42","author":"Ponti","year":"2006","journal-title":"Eur J Cancer"},{"issue":"9-10","key":"10.1016\/j.mehy.2021.110704_b0125","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1432-0436.2005.00047.x","article-title":"Stem\/progenitor and intermediate cell types and the origin of human prostate cancer","volume":"73","author":"Tokar","year":"2005","journal-title":"Differentiation"},{"issue":"43","key":"10.1016\/j.mehy.2021.110704_b0130","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.18632\/oncotarget.27783","article-title":"Regulation of breast cancer oncogenesis by the cell of origin\u2019s differentiation state","volume":"11","author":"Petrova","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.mehy.2021.110704_b0135","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/90.8.606","article-title":"Multiple primary cancers in families with Li-Fraumeni syndrome","volume":"90","author":"Hisada","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.mehy.2021.110704_b0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10911-008-9087-3","article-title":"Signal transduction in transgenic mouse models of human breast cancer - Implications for human breast cancer","volume":"13","author":"Marcotte","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"2","key":"10.1016\/j.mehy.2021.110704_b0145","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0002-9440(10)64211-3","article-title":"Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells","volume":"161","author":"O'Connell","year":"2002","journal-title":"Am J Pathol"},{"issue":"15","key":"10.1016\/j.mehy.2021.110704_b0150","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1056\/ENEJMicm020137","article-title":"Images in clinical medicine. Pseudomyxoma peritonei","volume":"350","author":"Barsky","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mehy.2021.110704_b0155","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41379-019-0302-0","article-title":"A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases","volume":"32","author":"Meagher","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.mehy.2021.110704_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-019-4816-9","article-title":"The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm","volume":"12","author":"Aldaoud","year":"2019","journal-title":"BMC Res Notes"},{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000332739","article-title":"Leptin, MUC2 and mTOR in appendiceal mucinous neoplasms","volume":"79","author":"Chang","year":"2012","journal-title":"Pathobiology"},{"key":"10.1016\/j.mehy.2021.110704_b0170","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3748\/wjg.v17.i30.3531","article-title":"Histological origin of pseudomyxoma peritonei in Chinese women: Clinicopathology and immunohistochemistry","volume":"17","author":"Guo","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.mehy.2021.110704_b0175","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1245\/s10434-007-9778-9","article-title":"Pseudomyxoma peritonei: Is disease progression related to microbial agents? A study of bacteria, MUC2 and MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis","volume":"15","author":"Semino-Mora","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.mehy.2021.110704_b0180","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1634\/theoncologist.2017-0081","article-title":"Appendiceal Mucinous Neoplasms: Diagnosis and Management","volume":"22","author":"Shaib","year":"2017","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.mehy.2021.110704_b0185","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","article-title":"Therapeutic options for mucinous ovarian carcinoma","volume":"156","author":"Gorringe","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.mehy.2021.110704_b0190","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0002-9440(10)65442-9","article-title":"Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women","volume":"154","author":"Szych","year":"1999","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.mehy.2021.110704_b0195","doi-asserted-by":"crossref","first-page":"480.e1","DOI":"10.1016\/j.ajog.2011.06.049","article-title":"Natural history and outcome of mucinous carcinoma of the ovary","volume":"205","author":"Schiavone","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.mehy.2021.110704_b0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2019.12.008","article-title":"Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases","volume":"97","author":"Yan","year":"2020","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.mehy.2021.110704_b0205","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1245\/s10434-017-6310-8","article-title":"Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC","volume":"25","author":"Reghunathan","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.mehy.2021.110704_b0210","doi-asserted-by":"crossref","unstructured":"Wang H, Wang X, Ju Y, Wang J, Zhang X, Cheng Y, et al. Clinicopathological features and prognosis of pseudomyxoma peritonei. Exp Ther Med 2013;7:185\u201390. https:\/\/doi.org\/10.3892\/etm.2013.1408.","DOI":"10.3892\/etm.2013.1408"},{"key":"10.1016\/j.mehy.2021.110704_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19061569","article-title":"Recent insights into mucinous ovarian carcinoma","volume":"19","author":"Ricci","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.mehy.2021.110704_b0220","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-018-6488-4","article-title":"Management of Mucinous Appendiceal Tumors","volume":"25","author":"Choudry","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.mehy.2021.110704_b0225","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9610(37)90763-3","article-title":"Mucocele of appendix with pseudomucinous degeneration","volume":"36","author":"Weaver","year":"1937","journal-title":"Am J Surg"},{"issue":"6","key":"10.1016\/j.mehy.2021.110704_b0230","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-014-0389-x","article-title":"Mucinous tumors of the ovary: Current thoughts on diagnosis and management","volume":"16","author":"Brown","year":"2014","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.mehy.2021.110704_b0235","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/jclinpath-2012-200843","article-title":"Pathology and prognosis in pseudomyxoma peritonei: A review of 274 cases","volume":"65","author":"Carr","year":"2012","journal-title":"J Clin Pathol"},{"issue":"2","key":"10.1016\/j.mehy.2021.110704_b0240","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s13193-016-0516-2","article-title":"Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei","volume":"7","author":"Ramaswamy","year":"2016","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.mehy.2021.110704_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-9-71","article-title":"Secreted mucins in pseudomyxoma peritonei: Pathophysiological significance and potential therapeutic prospects","volume":"9","author":"Amini","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0250","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000323137","article-title":"Immunohistochemical and biochemical characterization of Mucin in pseudomyxoma peritonei: A case study","volume":"5","author":"Mall","year":"2011","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.mehy.2021.110704_b0255","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0221-0363(08)73781-8","article-title":"Mucocele of the appendix and pseudomyxoma peritonei","volume":"89","author":"Fairise","year":"2008","journal-title":"J Radiol"},{"issue":"9","key":"10.1016\/j.mehy.2021.110704_b0260","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4240\/wjgs.v11.i9.358","article-title":"History of pseudomyxoma peritonei from its origin to the first decades of the twenty-first century","volume":"11","author":"Morera-Ocon","year":"2019","journal-title":"World J Gastrointest Surg"},{"key":"10.1016\/j.mehy.2021.110704_b0265","doi-asserted-by":"crossref","unstructured":"Husain AN, Colby T V, Ordo NG, Travis WD, Wick MR, Malignant C. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma A Consensus Statement from the International Mesothelioma Interest Group 2009;133. https:\/\/pubmed.ncbi.nlm.nih.gov\/19653732\/.","DOI":"10.5858\/133.8.1317"},{"key":"10.1016\/j.mehy.2021.110704_b0270","doi-asserted-by":"crossref","unstructured":"Liu L, Sun L, Wang J, Ji G, Chen B, Zhang H. Ovarian cystadenocarcinoma and pseudomyxoma peritonei. Case Reports 2010;2010:bcr0620080137\u2013bcr0620080137. https:\/\/doi.org\/10.1136\/bcr.06.2008.0137.","DOI":"10.1136\/bcr.06.2008.0137"},{"issue":"9","key":"10.1016\/j.mehy.2021.110704_b0275","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/01.MP.0000026617.52466.9F","article-title":"MUC2 is a molecular marker for pseudomyxoma peritonei","volume":"15","author":"O\u2019Connell","year":"2002","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0280","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0147-0272(88)80007-2","article-title":"Metastasis of unknown origin","volume":"12","author":"Haskell","year":"1988","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.mehy.2021.110704_b0285","doi-asserted-by":"crossref","unstructured":"Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ili\u00e9 M. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers (Basel) 2018;10. https:\/\/doi.org\/10.3390\/cancers10040108.","DOI":"10.3390\/cancers10040108"},{"key":"10.1016\/j.mehy.2021.110704_b0290","unstructured":"Hainsworth JD, Greco FA. Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine | ASCO Connection n.d. https:\/\/connection.asco.org\/magazine\/current-controversies-oncology\/cancer-unknown-primary-site-new-treatment-paradigms-era (accessed September 26, 2020)."},{"issue":"10","key":"10.1016\/j.mehy.2021.110704_b0295","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mehy.2021.110704_b0300","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5858\/arpa.2015-0173-CP","article-title":"Practical applications in immunohistochemistry: Carcinomas of unknown primary site","volume":"140","author":"Kandalaft","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.mehy.2021.110704_b0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah cannon research institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mehy.2021.110704_b0310","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/PAP.0000000000000069","article-title":"Metastatic carcinoma of unknown primary: Diagnostic approach using immunohistochemistry","volume":"22","author":"Conner","year":"2015","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.mehy.2021.110704_b0315","article-title":"Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site","volume":"11","author":"Qaseem","year":"2019","journal-title":"Cureus"},{"issue":"81","key":"10.1016\/j.mehy.2021.110704_b0320","doi-asserted-by":"crossref","first-page":"35278","DOI":"10.18632\/oncotarget.26233","article-title":"ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: A case report","volume":"9","author":"Taniwaki","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.mehy.2021.110704_b0325","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00292-018-0518-7","article-title":"Transcription factors in tumor diagnosis","volume":"39","author":"Moll","year":"2018","journal-title":"Pathologe"},{"issue":"27","key":"10.1016\/j.mehy.2021.110704_b0330","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2007.14.4378","article-title":"Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation","volume":"26","author":"Varadhachary","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.mehy.2021.110704_b0335","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1634\/theoncologist.2009-0328","article-title":"Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction","volume":"15","author":"Greco","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.mehy.2021.110704_b0340","unstructured":"Mishra M, Morgan V, Hamati AK, Al-Abbadi M. Carcinoma of unknown primary: check the liver... thanks to TTF-1. Tenn Med 2012;105(1):35-6,40. PMID: 22359993. https:\/\/pubmed.ncbi.nlm.nih.gov\/22359993\/."},{"issue":"5","key":"10.1016\/j.mehy.2021.110704_b0345","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/dc.20393","article-title":"Immunocytochemical identification of carcinomas of unknown primary in serous effusions","volume":"33","author":"Pomjanski","year":"2005","journal-title":"Diagn. Cytopathol."},{"key":"10.1016\/j.mehy.2021.110704_b0350","article-title":"Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach","author":"Deyoung","year":"2000","journal-title":"Semin Diagn Pathol"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2021.110704_b0355","first-page":"41","article-title":"Carcinoma of unknown primary (CUP); some considerations about pathogenesis and diagnostic strategy, particularly focusing on CUPS pertaining to the Urology","volume":"33","author":"Alberti","year":"2012","journal-title":"G Chir"},{"issue":"13","key":"10.1016\/j.mehy.2021.110704_b0360","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.7150\/jca.42880","article-title":"Cancer of unknown primary site: Real entity or misdiagnosed disease?","volume":"11","author":"Alshareeda","year":"2020","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.mehy.2021.110704_b0365","article-title":"Transcriptome analyses of tumor-adjacent somatic tissues reveal genes co-expressed with transposable elements. Mob","volume":"10","author":"Chung","year":"2019","journal-title":"DNA"},{"issue":"9","key":"10.1016\/j.mehy.2021.110704_b0370","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2009-10-9-r100","article-title":"LINE1 elements contribute to the transcriptome of human somatic cells","volume":"10","author":"Rangwala","year":"2009","journal-title":"Genome Biol"},{"key":"10.1016\/j.mehy.2021.110704_b0375","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0014-4800(03)00011-X","article-title":"Myoepithelial mRNA expression profiling reveals a common tumor-suppressor phenotype","volume":"74","author":"Barsky","year":"2003","journal-title":"Exp Mol Pathol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721002231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987721002231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:26:42Z","timestamp":1759692402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987721002231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":75,"alternative-id":["S0306987721002231"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110704","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cell of cancer origin provides the most reliable roadmap to its diagnosis, prognosis (biology) and therapy","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2021.110704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110704"}}